Act directly on the heart with Entresto to improve cardiac function1–3
Entresto, a first-in-class angiotensin receptor-neprilysin inhibitor, has a dual mode of action that simultaneously inhibits vasoconstriction and promotes vasodilation.1
Indication: Entresto is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction.1
HFrEF, heart failure with reduced ejection fraction.
- Entresto Summary of Product Characteristics, 2020
- Desai AS et al. JAMA 2019; 322(11): 1077–1084.
- Januzzi JL Jr et al. JAMA 2019; 322(11): 1085–1095.